



Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin

Langer, I., Tikhonova, I. G., Travers, M-A., Archer-Lahlou, E., Escrieut, C., Maigret, B., & Fourmy, D. (2005). Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin. *Journal of Biological Chemistry*, 280(23), 22198-22204. DOI: 10.1074/jbc.M501786200

Published in:

Journal of Biological Chemistry

Document Version:

Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:

[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2005 The American Society for Biochemistry and Molecular Biology, Inc

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Evidence That Interspecies Polymorphism in the Human and Rat Cholecystokinin Receptor-2 Affects Structure of the Binding Site for the Endogenous Agonist Cholecystokinin*

Received for publication, February 16, 2005, and in revised form, April 1, 2005
Published, JBC Papers in Press, April 7, 2005, DOI 10.1074/jbc.M501786200

Ingrid Langer^{‡§¶}, Irina G. Tikhonova^{‡§}, Marie-Agnès Travers[‡], Elodie Archer-Lahlou[‡],
Chantal Escricuet[‡], Bernard Maigret^{||}, and Daniel Fourmy^{‡**}

From the [‡]Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Louis Bugnard, CHU Rangueil, 31432 Toulouse Cedex 4, France and ^{||}Laboratoire de Chimie Théorique, Université de Nancy, 54506 Vandoeuvre, Nancy, France

The cholecystokinin (CCK) receptor-2 exerts very important central and peripheral functions by binding the neuropeptides cholecystokinin or gastrin. Because this receptor is a potential therapeutic target, great interest has been devoted to the identification of efficient antagonists. However, interspecies genetic polymorphism that does not alter cholecystokinin-induced signaling was shown to markedly affect activity of synthetic ligands. In this context, precise structural study of the agonist binding site on the human cholecystokinin receptor-2 is a prerequisite to elucidating the molecular basis for its activation and to optimizing properties of synthetic ligands. In this study, using site-directed mutagenesis and molecular modeling, we delineated the binding site for CCK on the human cholecystokinin receptor-2 by mutating amino acids corresponding to that of the rat homolog. By doing so, we demonstrated that, although resembling that of rat homolog, the human cholecystokinin receptor-2 binding site also displays important distinct structural features that were demonstrated by susceptibility to several point mutations (F120A, Y189A, H207A). Furthermore, docking of CCK in the human and rat cholecystokinin receptor-2, followed by dynamic simulations, allowed us to propose a plausible structural explanation of the experimentally observed difference between rat and human cholecystokinin-2 receptors.

Cholecystokinin (CCK)¹ and gastrin are two regulatory peptides having high affinity for CCK receptors. Both peptides share an identical carboxyl-terminal pentapeptide sequence but differ in their selectivity for the two CCK receptor subtypes, the CCK1 (CCK1R) and the CCK2 (CCK2R) receptors, on the basis of tyrosine sulfation at the seventh position (CCK) or at the sixth position (gastrin) from the carboxyl terminus.

* This work was supported in part by a grant from Association pour la Recherche contre le Cancer ARC 4430 and 3282. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Recipients of a fellowship from Fondation pour la Recherche Médicale.

¶ Present address: Faculté de Médecine-Université Libre de Bruxelles, Laboratoire Chimie Biologique, 808 Route de Lennik CP611, B-1070 Brussels, Belgium.

** To whom correspondence should be addressed: Institut Frédéric Joliot de Recherche 31, Institut Louis Bugnard, BP 84225, Unité 531, 31432 Toulouse cedex 4, France. E-mail: fourmyd@toulouse.inserm.fr.

¹ The abbreviations used are: CCK, cholecystokinin; CCK1R, cholecystokinin 1 receptor; CCK2R, cholecystokinin 2 receptor; DMEM, Dulbecco's modified Eagle's medium; TM, transmembrane.

Although both receptors recognize sulfated CCK with comparable high affinity, the CCK2R has high affinity for both sulfated and non-sulfated gastrin (1, 2). CCK1R and CCK2R are seven-transmembrane spanning receptors that belong to the superfamily of G protein-coupled receptors and have ~50% homology (3–5). CCK1Rs are mainly found in the peripheral organs, where they regulate pancreatic secretion and gallbladder and gastrointestinal motility, but are also found in some areas of the central nervous system, where they regulate satiety and analgesia. CCK2Rs are predominantly present throughout the central nervous system, where they regulate anxiety/panic attacks and dopamine release, implicated in the pathogenesis of dopaminergic related movement and behavioral disorders in humans. In the gut, CCK2Rs regulate acid and histamine secretions, gastrointestinal motility, as well as growth in the gastric mucosa (1, 2). The important physiological functions mediated by CCK receptors, and therefore their possible implication in associated disorders, have generated considerable interest in the identification of ligands that selectively activate or block CCK1R and CCK2R (6). To date, a large panel of such molecules has been designed covering a wide range of functional activities, such as full, partial, and inverse agonists, as well as antagonists (6). Pharmacological characterization of selective synthetic CCK2R ligands among different species pointed out an interspecies genetic polymorphism that does not alter endogenous hormone-induced signaling but markedly affects both the affinity and activity of synthetic ligands (7). This is the case for L-365,260 and L-364,718, two reference non-peptidic CCK2R antagonists that present reversal in the affinity rank order on canine or human recombinant CCK2R despite a 93% identity in their protein sequence (8). Furthermore, efficacy of PD-135,158, a CCK2R partial agonist, is 60% of CCK-induced maximal production of inositol phosphates on mouse CCK2R but only 20% on human CCK2R, despite 90% identity (9). These interspecies differences toward synthetic ligands were shown to be caused by sequence variations within the binding site of the CCK2R (7). Such data pointed out the high importance of *in vivo* and *in vitro* tests with human protein targets.

The aims of the present study, using site-directed mutagenesis and molecular modeling, were to delineate the binding site for CCK on the human CCK2R and to investigate whether insensitivity of endogenous ligands to interspecies polymorphism between rat and human CCK2R can be explained by differences in their positioning into the CCK2R binding site or whether they are related to distinct susceptibilities to mutations. For that purpose, we took advantage of our previous data, which demonstrated an interaction between His²⁰⁷ of rat

CCK2R and Asp⁸ of CCK, between the Tyr¹⁸⁹ and Asn³⁵⁸ residues of rat CCK2R and the carboxyl-terminal amide of CCK (10), as well as the contribution of Arg⁵⁷ and Phe¹²⁰ residues in CCK high affinity binding (11, 12). These key amino acids of the CCK2R binding site were mutated in the human CCK2R, and the mutant receptors were characterized for CCK affinity, as well as efficacy and potency, to stimulate inositol phosphates accumulation. By doing so, we demonstrated that, although resembling that of rat CCK2R, the human CCK2R binding site also displays important distinct structural features that are confirmed by susceptibility to point mutations and docking, followed by dynamic simulations.

EXPERIMENTAL PROCEDURES

Materials—Sulfated [Thr²⁸,Nle³¹]CCK25–33 (H-Arg-Asp-Tyr(SO₃H)-Thr-Gly-Trp-Nle-Asp-Phe-NH₂, CCK9S), was synthesized as described previously (13). ¹²⁵I-Sodium (2000 Ci/mmol) was from Amersham Biosciences. Sulfated [Thr²⁸,Nle³¹]CCK25–33 was conjugated with Bolton-Hunter reagent, purified, and radioiodinated as described previously (14) and is referred to as [¹²⁵I]CCK9S.

Site-directed Mutagenesis and Transfection of COS-7 cells—All mutant receptor cDNAs were constructed by oligonucleotide-directed mutagenesis (QuikChangeTM site-directed mutagenesis kit, Stratagene) using the human CCK2R cDNAs cloned into pRFENeo vector as a template. The presence of the desired and the absence of undesired mutations were confirmed by automated sequencing of the complete CCK2R coding sequence (Applied Biosystems).

COS-7 cells (1.5×10^6) were plated onto 10-cm culture dishes and grown in Dulbecco's modified Eagle's medium (DMEM) containing 5% fetal calf serum in a 5% CO₂ atmosphere at 37 °C. After overnight incubation, the cells were transfected with 0.5 µg/plate of pRFENeo vectors containing the cDNA for the wild-type or mutated CCK₂ receptors, using a modified DEAE-dextran method as described previously (10). The cells were transferred to 24-well plates at a density of 20,000–150,000 cells/well 24 h after transfection, depending on the transfected mutant and the experiment to be performed.

Binding Experiments—Approximately 24 h after the transfer of the transfected cells to 24-well plates, the cells were washed with phosphate-buffered saline, pH 7.4, containing 0.1% bovine serum albumin and then incubated for 60 min at 37 °C in 0.3 ml of DMEM containing 0.1% bovine serum albumin, with either 50 pM (wild-type CCK2R, R356K), 100 pM (R57A, F120A, Y189F), 250 pM (H207A, N358A, Y189A, R356A, R356H) or 500 pM (R356D) [¹²⁵I]CCK9S in the presence or in the absence of unlabeled CCK9S. The cells were washed twice with cold phosphate-buffered saline, pH 7.4, containing 2% bovine serum albumin, and cell-associated radioligand was collected by cell lysis with NaOH 0.1 N. The radioactivity was directly counted in a γ counter (Auto-γ, Packard, Downers Grove, IL). Receptor density and K_d were calculated from homologous [¹²⁵I]CCK9S/CCK9S competition binding experiments using Ligand software (Kell, Cambridge, UK). K_i values were calculated using the non-linear curve fitting software GraphPad Prism (San Diego, CA).

Inositol Phosphate Assay—Approximately 24 h after the transfer to 24-well plates and following overnight incubation in DMEM containing 2 µCi/ml myo-2-[³H]inositol (Amersham Biosciences), the transfected cells were washed with DMEM and then incubated for 30 min in 1 ml/well DMEM containing 20 mM LiCl at 37 °C. The cells were washed with inositol phosphate buffer, pH 7.45, phosphate-buffered saline containing 135 mM NaCl, 20 mM HEPES, 2 mM CaCl₂, 1.2 mM MgSO₄, 1 mM EGTA, 10 mM LiCl, 11.1 mM glucose, and 0.5% bovine serum albumin. The cells were then incubated for 60 min at 37 °C in 0.3 ml of inositol phosphate buffer with or without increasing CCK9S concentration. The reaction was stopped by adding 1 ml of methanol/HCl to each well, and the content was transferred to a column (Dowex AG 1-X8, formate form, Bio-Rad, Hercules, CA) for the determination of inositol phosphates. The columns were washed twice with 3 ml of distilled water and twice with 2 ml of 5 mM sodium tetraborate/60 mM sodium formate. The content of each column was eluted by the addition of 2 ml of 1 M ammonium formate/100 mM formic acid. Radioactivity of 1 ml of the eluted fraction was evaluated using a liquid scintillation counter (Packard Instrument Co.). EC₅₀ values were calculated from dose effect curves by non-linear regression curve fitting using GraphPad Prism software (San Diego, CA).

Molecular Modeling of Human CCK2R-CCK Complex and Dynamic Simulations—The human CCK2R model was built by homology modeling from the rat CCK2R-CCK complex model described by Gales

et al. (11) using Insight II modules (Homology, Discover 3, Biopolymer, Accelrys, San Diego, CA). Alignment of the human CCK2R sequence on the rat CCK2R sequence was performed using the alignment procedure followed by manual refinement so that motifs common to all G protein-coupled receptors and conserved amino acids between the two sequences precisely matched. The coordinates of the human CCK2R were then assigned to those of the rat CCK2R three-dimensional model, based on this alignment. The resulting model was finally submitted to energy minimization by the steepest descent (until convergence to 2 kcal/mol/Å) and conjugated gradient (until convergence to 0.01 kcal/mol/Å) to remove steric clashes. During minimization, C-α trace was tethered using a quadratic potential. This was performed using the Discover 3 module with the consistent force field. The non-bond cutoff method and the dielectric constant were set up to cell multipole and were distance-dependent, respectively ($\epsilon = r$). The minimized model of human CCK2 receptor was used to perform manual docking of CCK. The conformation of CCK was taken from the optimized complex of rat CCK2R-CCK (11), and docking was performed taking into account the position of CCK in that receptor. The obtained human CCK2R-CCK complex was minimized again according to the previously described minimization protocol, with no C-α restraints, and was further subjected to molecular dynamics in a two-step procedure. In the first step, the complex was heated from 10 K up to 300 K during 5000 fs, and in the second step, it was kept at 300 K until equilibration. The tethering force on the C-α trace was kept in heating and was successively decreased by reducing the force constant value of the quadratic potential from 100 to 80, 50, 30, 10, and 0 every 1000 ps in the second step. The integration time step was set up to 1 fs, and the calculations were performed at constant volume and temperature. A snapshot of the system was saved every 100 fs. Once the system was equilibrated, the coordinates of 20 snapshots were averaged and submitted again to the previously mentioned minimization protocol, with no C-α restraints.

RESULTS

Effects of R57A, F120A, H207A, Y189F, Y189A, and N353A Mutations in the Human CCK2R on CCK Affinity and Potency—Human R57A, F120A, H207A, Y189A, Y189F, and N353A mutants were constructed and transiently expressed in COS-7 cells. Scatchard analysis of [¹²⁵I]CCK9S binding to the wild-type human CCK2R indicated that CCK9S binds to high affinity sites with K_i values of 0.75 ± 0.03 nM (B_{\max} 3.2 ± 0.3 pmol/10⁶ cells) (Tables I and II). Mutation of Arg⁵⁷ and Phe¹²⁰ in alanine or mutation of Tyr¹⁸⁹ in phenylalanine slightly reduced, between 4- and 6-fold, CCK9S affinity with K_i values of 3.4 ± 0.4 nM (B_{\max} 0.85 ± 0.09 pmol/10⁶ cells), 3.1 ± 0.4 nM (B_{\max} 0.79 ± 0.08 pmol/10⁶ cells), and 4.3 ± 0.4 nM (B_{\max} 1.1 ± 0.2 pmol/10⁶ cells), respectively (Tables I and II). Y189A, H207A, and N353A mutants displayed between 25- and 73-fold decreased affinity for CCK9S with respective K_i values of 55 ± 8 nM (B_{\max} 2.7 ± 0.5 pmol/10⁶ cells), 19 ± 2 nM (B_{\max} 1.1 ± 0.1 pmol/10⁶ cells), and 20 ± 2 nM (B_{\max} 0.8 ± 0.1 pmol/10⁶ cells) (Tables I and II). In agreement with binding data, the potency of CCK9S to stimulate inositol phosphate accumulation was reduced for all mutants (EC₅₀) and directly correlated with the loss of affinity for CCK9. The mutants displayed CCK9S efficacy (E_{\max} , Table I) comparable with that of wild-type CCK2R, except for the Y189A mutant, which presented a 44% decrease of CCK9S maximal effect despite similar receptor density (Table I). Comparison of these results with those from our previous studies performed in exactly the same experimental conditions on rat CCK2R mutants reveals that, except for N353A mutation (the human corresponding mutant of rat N358A), all of the mutations carried out on the human CCK2R less markedly affected CCK affinity and activity, supporting the view that the corresponding residues are differentially involved in the binding sites of the two CCK2Rs (Table II, F_{wt}).

Effects of R356A, R356H, R356K, and R356D Mutations in Human CCK2R on CCK Affinity and Potency—Our previous studies (15) on the binding site of the human CCK1R demonstrates that Arg³³⁶, located at the top of TM 6, highly contributes to the binding of CCK. Because the homologous amino acid

TABLE I
Effects of mutations of amino acids of the human CCK2R on binding affinity and biological activity of CCK9S

Binding properties and biological potency of mutated CCK2R were determined as described under "Experimental Procedures." Mutation factors (F_{wt}) were calculated as K_d (mutated CCK2R)/ K_d (WT-CCK2R) or EC_{50} (mutated CCK2R)/ EC_{50} (WT-CCK2R). E_{max} values are expressed in percent of wild-type receptor maximal inositol accumulation in response to 1 μ M CCK9S. Results represent the means \pm S.E. of at least three independent experiments performed in duplicate on separately transfected COS-7 cells.

	Binding						Inositol phosphate production		
	High affinity		Low affinity		B_{max}		EC_{50}	F_{WT}°	E_{max}
	K_{d1}	F_{1WT}°	K_{d2}	F_{2WT}°	High affinity	Low affinity			
	nM		nM		pmol/10 ⁶ cells		nM		
WT	0.37 \pm 0.02	1	2.8 \pm 0.3	1	0.89 \pm 0.05	2.3 \pm 0.2	0.34 \pm 0.05	1	100
R57A	1.3 \pm 0.3 ^a	4	22 \pm 3 ^a	8	0.19 \pm 0.04	0.66 \pm 0.05	2.2 \pm 0.4 ^a	6	100 \pm 2
F120A	1.2 \pm 0.2 ^a	3	17 \pm 4 ^a	6	0.14 \pm 0.03	0.65 \pm 0.05	1.6 \pm 0.2 ^a	5	99 \pm 2
Y189F	3.2 \pm 0.5 ^a	9	21 \pm 4 ^a	8	0.28 \pm 0.05	0.82 \pm 0.18	3.7 \pm 0.4 ^a	11	97 \pm 3
Y189A	50 \pm 5 ^a	136	436 \pm 24 ^a	156	0.45 \pm 0.05	2.2 \pm 0.5	37 \pm 6 ^a	109	56 \pm 2 ^a
H207A	8.3 \pm 1.4 ^a	27	51 \pm 5 ^a	18	0.31 \pm 0.05	0.78 \pm 0.13	12 \pm 2 ^a	35	97 \pm 2
N353A	12 \pm 1 ^a	32	114 \pm 5 ^a	41	0.17 \pm 0.06	0.62 \pm 0.04	11 \pm 1 ^a	32	99 \pm 2
R356K	0.38 \pm 0.02	1	3.2 \pm 0.4	1	1.1 \pm 0.1	2.8 \pm 0.3	0.54 \pm 0.06	1.6	100 \pm 2
R356H	3.8 \pm 0.3 ^a	10	51 \pm 10 ^a	18	0.21 \pm 0.05	0.71 \pm 0.13	4.1 \pm 0.5 ^a	12	100 \pm 3
R356A	28 \pm 2 ^a	76			0.49 \pm 0.04		22 \pm 4 ^a	65	100 \pm 3
R356D	345 \pm 35 ^a	932			1.1 \pm 0.1		76 \pm 6 ^a	224	100 \pm 2

^a p < 0.05 evaluated by Mann-Whitney test as compared to wild-type receptor value.

TABLE II
Differential effects of mutations of human or rat CCK2R on CCK9S affinity and potency

Binding properties and biological potency of mutated CCK2R were determined as described under "Experimental Procedures." Mutation factors (F_{wt}) were calculated as K_d (mutated CCK2R)/ K_d (WT-CCK2R) or EC_{50} (mutated CCK2R)/ EC_{50} (WT-CCK2R). E_{max} values are expressed in percent of wild-type receptor maximal inositol accumulation in response to 1 μ M CCK9S. Results represent the means \pm S. E. of at least three independent experiments performed in duplicate on separately transfected COS-7 cells.

	Human CCK2R				Rat CCK2R		Ref.
	Binding		IP accumulation		Binding	IP accumulation	
	K_i	F_{WT}°	EC_{50}	F_{WT}°	F_{WT}°	F_{WT}°	
	nM		nM				
CCK2	0.75 \pm 0.03	1	0.34 \pm 0.05	1	1	1	12
R57A	3.4 \pm 0.4 ^a	5	2.2 \pm 0.4 ^a	6	21		12
F120A	3.1 \pm 0.4	4	1.6 \pm 0.2 ^a	5		440	11
Y189F	4.3 \pm 0.4 ^a	6	3.7 \pm 0.4 ^a	11	30	61	10
Y189A	55 \pm 8 ^a	73	37 \pm 6 ^a	109 ^a	842	NA ^b	11
H207A	19 \pm 2 ^a	25	12 \pm 2 ^a	35	456	302	10
N353A	20 \pm 2 ^a	27	11 \pm 1 ^a	32	19	30	11

^a p < 0.05 evaluated by Mann-Whitney test as compared to wild-type receptor value.

^b NA, no accumulation of inositol phosphates.

in the human CCK2R is Arg³⁵⁶, we determined whether this residue could also be involved in the binding site of the human CCK2R. For this purpose, R356A, R356H, R356K, and R356D mutants were constructed and analyzed. These mutants were designed to remove partially or completely the positive charges of this arginine (R356A, R356H, and R356K mutants) or to introduce a negative charge at that position (R356D mutant). Mutation of Arg³⁵⁶ in lysine did not modify CCK9S affinity (K_i = 0.50 \pm 0.05 nM, B_{max} 3.9 \pm 0.4 pmol/10⁶ cells) nor the potency and efficacy of CCK9S to stimulate inositol phosphate accumulation (EC_{50} = 0.54 \pm 0.06 nM). Replacement of Arg³⁵⁶ by a histidine or an alanine reduced 10- and 76-fold, respectively, CCK9S affinity, whereas R356D displayed a 932-fold lower affinity relative to the high affinity component of the wild-type human CCK2R (Table I and Fig. 1). In agreement with binding data, R356H, R356A, and R356D mutants displayed reduced CCK9S potencies to stimulate inositol phosphate accumulation but unchanged efficacy (Table I and Fig. 1). These results indicate that positive charges of the amino acid side chain at position 356 of the CCK2R are important for high affinity binding of CCK.

Structural Study of Human CCK2R Binding Site Using Docking and Dynamic Simulations—Results from the current site-directed mutagenesis study support the view that homologous residues in the human CCK2R binding sites are differentially involved in the binding site of CCK compared with rat CCK2R, which we previously characterized. Because human

and rat CCK2R present non-conserved amino acids in extracellular domains and transmembrane helices (Fig. 2), in a first attempt to explain distinct involvement of His²⁰⁷, we exchanged the neighboring amino acid, namely Val²⁰⁶, for the corresponding amino acid of the rat sequence, Met. However, the resulting CCK2R mutant (V206MH207A) did not display an altered pharmacological profile, as compared with the human H207A mutant (not shown). We also considered the possibility that His²⁰⁷, which can exist in different tautomeric forms, could be differently protonated in human and rat CCK2R. However, pK calculations using the Poisson-Boltzmann equation and the generalized Born approach (embodied in the website chekhov.cs.vt.edu/completion/index.php) yielded similar values (pK, for rat 3.3 and 4.2, and for human 3.5 and 4.6) thus ruling out this hypothesis. This led us to hypothesize that non-conserved amino acids, including those in transmembrane helices, likely act collectively to position differently CCK in the binding site of the human CCK2R relative to the rat CCK2R. We therefore performed *in silico* experiments by building a three-dimensional structure of the human CCK2R-CCK complex based on the coordinates of the rat CCK2R-CCK complex that we previously experimentally validated (11). Thereafter, we applied molecular dynamics to assess whether variations in the CCK2R sequence could result in a distinct location of CCK that could explain pharmacological results. A simplified view of the obtained human CCK2R-CCK complex is presented in Fig. 3, A and C. The docking, followed by dynamic simula-




FIG. 1. **Importance of R356 of CCK2R for binding of CCK (A) and production of inositol phosphates (B).** A, CCK9S competition curves of specific [125 I]CCK9S binding. B, dose-effected curves of CCK9S. Both induced inositol phosphate production in COS cells expressing wild-type CCK2R (close circles), R356K (open circles), R356H (open squares), R356A (open triangles), or R356D (open diamonds) mutants. Results represent the means \pm S.E. of three independent experiments in duplicate performed on separately transfected COS-7 cells.




FIG. 2. **Serpentine representation of the human CCK2R.** On this representation of the human CCK2R, amino acids Arg⁵⁷, Phe¹²⁰, His²⁰⁷, Tyr¹⁸⁹, Asn³⁵³, and Arg³⁵⁶, which are corresponding amino acids of the rat CCK2R binding site of CCK, are indicated. Moreover, non-conserved amino acids between human and rat CCK2R are shown and numbered. Ψ , potential N-glycosylation sites.

tions, revealed that Arg¹ and Asp² of CCK form internal ionic bonds; sulfated Tyr³ of CCK is in ionic interaction with Arg⁵⁷ and makes a hydrogen bond with Tyr⁶¹; Thr⁴ forms a hydrogen bond with Arg³⁵⁶; Trp⁶ forms both a hydrogen bond with His³⁷⁶ and aryl sulfur interactions with Met⁶⁷ and Cys¹⁰⁷ and hydrophobic interactions with Phe¹²⁰ and Phe¹¹⁰; Nle⁷ lies in an hydrophobic pocket composed of Pro³⁷¹, Trp³⁵⁵, and Leu³⁶⁷; the carboxyl group of Asp⁸ interacts with Arg³⁵⁶ and Ser¹³¹; the phenyl group of Phe⁹ is sited in an aromatic pocket made of Tyr¹⁸⁹, Tyr¹⁹², Tyr³⁵⁰, Trp³⁴⁶, Phe³⁴², and Phe²²⁷; and the carbonyl group of CCK amide forms hydrogen bond with the hydroxyl group of Tyr¹⁸⁹, whereas $-\text{NH}_2$ of the CCK amide interacts with Asn³⁵³ and Thr¹⁹³ (Fig. 3A). According to these results, the binding site of the human CCK2R resembles that of the rat CCK2R. However, and importantly, CCK drifts deeper in the human CCK2R, representing a difference of ~ 1.5 Å, and the C-terminal part of CCK between Trp⁶ and Phe⁹ displays a deviation of the backbone of >2.5 Å, as compared with rat CCK2R-CCK complex, which was subjected to the same procedure of dynamic simulations (see Fig. 3C for comparison). In addition, the phenyl group of Phe⁹ has an affected orientation, as compared with the rat complex, where it approximated Tyr¹⁸⁹. In the human complex, Phe⁹ seems more inserted in a

cavity composed of Tyr¹⁸⁹, Tyr¹⁹², Tyr³⁵⁰, Trp³⁴⁶, Phe³⁴², and Phe²²⁷ (Fig. 3, A and B). Moreover, Asp⁸ forms stable ionic interactions mostly with Arg³⁵⁶ but less with His, which dominated in the rat complex.

DISCUSSION

Despite the high degree of homology between species homologs of the CCK2 receptor (ranging from 84 to 93%), pharmacological studies have demonstrated that interspecies polymorphism can significantly alter both the affinity and activity of synthetic ligands (7). Other examples describing polymorphism-induced alteration can be found in the literature for neurokinin, serotonin, and VIP receptors (16–18), but in those cases, both endogenous and synthetic ligands are affected. However, in the case of CCK2R, comparison of CCK or gastrin affinity and activity in cells that express canine, murine, or human recombinant CCK2R revealed similar profiles. It is suggested that the apparent insensitivity of endogenous ligand to receptor polymorphism might be explained by evolutionary selection, which resulted in the elimination of receptor variants that compromised endogenous ligand function (7). In this context, the aim of the present study was to delineate the binding site for CCK on the human CCK2R and to investigate whether




FIG. 3. **Modeled structure of the CCK2R binding site for CCK.** *a*, the human CCK2R binding site. This side view shows the three-dimensional refined model of the active high affinity human CCK2R binding site. The model was built by homology, as described under "Experimental Procedures," using a previously validated rat CCK2R model as a template. Thereafter, the three-dimensional model was refined according to the method detailed under "Experimental Procedures." The program package from Accelrys (San Diego, CA) was used. For clarity, the view shows only identified amino acid side chains of the CCK2R (green) in interaction with CCK (orange). *b*, focused side view of the binding site of the C-terminal end of CCK in the human CCK2R. This view shows how the C-terminal Phe of CCK (orange) is inserted in a cavity formed of aromatic residues (green), the relative position of which is maintained by quadrupole-quadrupole interactions between Met²³⁴ and Phe³⁴². *c* and *d*, comparison between human and rat CCK2R binding sites for CCK. Rat and human CCK2R protein traces were superimposed. The CCK2Rs are shown from two different angles of view to better display differences at the top of binding sites (*c*) and within the deepest part of the binding cavity (*d*). In human CCK2R (dark green residues and numbering), carbon atoms of CCK are shown in orange. In the rat CCK2R (pink residues and numbering), carbon atoms of CCK are shown in cyan.

insensitivity of endogenous ligands to interspecies polymorphism between rat and human CCK2R can be explained by differences in their location into the CCK2R binding site or whether there are related to distinct susceptibilities to mutations.

Using site-directed mutagenesis and pharmacological studies, we found that some mutations were less unfavorable when performed on the human CCK2R than on the rat receptor. The magnitude of the differences between rat and human mutants varied depending on the amino acid studied. Mutation of Arg⁵⁷ (located at the top of the first transmembrane domain) in alanine reduced 5-fold the CCK affinity in the human receptor versus 21-fold in rat receptor (12). Similarly, Kopin *et al.* (19)

have shown that the human R57Q mutant displayed a 6-fold decreased affinity for CCK, confirming the slight contribution of Arg⁵⁷ in the human CCK2R for high affinity binding of CCK. Moreover, photoaffinity labeling experiments, using a CCK ligand having its photosensitive moiety attached to its N terminus, identified amino acids at the top of helix I, which agrees with current results supporting that the sulfate of CCK slightly interacts with Arg⁵⁷ (20). Surprisingly, Phe¹²⁰, located in the first extracellular loop and which is essential for the high affinity binding of CCK to the rat CCK2R, does not appear to be as essential in human CCK2R. Indeed, mutation F120A in the rat receptor resulted in complete loss of radioligand binding (12), whereas in the current study, the human F120A mutant

only displayed a 4-fold lower affinity as compared with wild-type CCK2R. Similar results were obtained with the H207A mutant. Our previous results with the rat receptor clearly demonstrated a direct interaction between His²⁰⁷, located in the second extracellular loop, and penultimate aspartic acid of CCK (10). Here, the contribution of His²⁰⁷ in the human CCK2R binding pocket is quantitatively different. Indeed, the human H207A mutant displayed a 25-fold lower CCK affinity *versus* 456-fold in the rat (10). Taken together, all of the results thus suggest that the contribution of extracellular residues of human CCK2R is less important than in the rat CCK2R, and most of the residues involved in high affinity binding of CCK are probably located in transmembrane domains.

We next evaluated, in human CCK2R, the contribution of Tyr¹⁸⁹ and Asn³⁵³, the corresponding amino acids of rat Tyr¹⁸⁹ and Asn³⁵⁸ known to make direct interaction with the C-terminal amide of CCK (11). Human N353A and rat N358A mutants displayed a similar pharmacological profile with respect to CCK affinity and activity, suggesting that, as in the rat receptor, Asn³⁵³ located at the top of the sixth transmembrane domain directly interacts with the C-terminal amide of CCK. In contrast, the contribution of Tyr¹⁸⁹ is different in human and rat receptors. Mutation of Tyr¹⁸⁹, located at the top of the fourth transmembrane domain, in phenylalanine or alanine reduced by 6- and 73-fold CCK affinity in the human receptor *versus* 30- and 842-fold in the rat receptor, respectively. In addition, the human Y189A mutant displayed a reduced CCK potency (109-fold) and efficacy (44%) to stimulate inositol phosphate accumulation, whereas the rat Y189A mutant was found to be unable to produce inositol phosphates (11). Even if human Y189A mutant is less affected than rat Y189A mutant, our results are compatible with an involvement of the Tyr¹⁸⁹ aromatic ring in CCK2R activation (reduced potency and efficacy). We also evaluated the contribution of Arg³⁵⁶, located at the top of the sixth transmembrane domain. Mutation of Arg³⁵⁶ in lysine did not modify CCK affinity, whereas its mutation in histidine or alanine reduced by 9- and 76-fold CCK affinity, respectively, suggesting that the presence of positive charges is important for high affinity binding of CCK. The R356D mutant displays an even lower affinity for CCK (413-fold reduction) that likely reflects electrostatic repulsion between CCK and R356D mutant. Interestingly, we previously demonstrated that, in human CCK1R, the corresponding amino acid (Arg³³⁶) interacts with the penultimate aspartic acid of CCK (15).

Detailed analysis of the human- and rat-modeled CCK2R-CCK complexes allows us to propose structure-based explanations for the different mutational data obtained in human and rat CCK2R. According to dynamic simulations, CCK drifts deeper in the human CCK2R than in the rat CCK2R, leading the peptidic backbone corresponding to the C-terminal region of CCK (which is the most important for recognition by the CCK2R) to site >2.5 Å deeper in the receptor binding pocket. This can influence the contributions of several extracellular key residues to the binding of CCK, especially because these belong to flexible extracellular loops 1 and 2. For example, Phe¹²⁰ is less important for CCK recognition in human CCK2R than in rat CCK2R. This is likely the result of an increase of the collective contribution of other residues, such as His³⁷⁶, Met⁶⁷, Cys¹⁰⁷, and Phe¹¹⁰, to the binding site of the human CCK2R. This view fully agrees with previous mutagenesis data showing that exchange of His³⁷⁶ for a leucine decreased the affinity of CCK8 for the human CCK2R by 30-fold, whereas mutation of the corresponding amino acid in the rat CCK2R did not affect CCK8 recognition (19, 21).

Thereafter, we demonstrated that different contributions of His²⁰⁷ in human *versus* rat CCK2R were likely not due to

different protonated states. Alternatively, the deepest location of the CCK molecule within the binding site of the human CCK2R compared with rat CCK2R could favor interactions of the Asp side chain of CCK with Arg³⁵⁶, to the detriment of His²⁰⁷. Furthermore, there is a Val at position 130 in human CCK2 and an Ile in the rat receptor. Due to the possible hindrance of amino acid side chains, one can suggest that the Val residue favors interaction with Arg³⁵⁶, whereas Ile can favor interaction with His²⁰⁷.

Concerning the lower contribution of Tyr¹⁸⁹ in the human CCK2R binding site (as compared with rat CCK2R), in both cases, two types of interactions are seen in the modeled structure: a hydrogen bond with the carbonyl group of Phe⁹ of CCK and π - π electronic interactions between the two rings. However, the relative positions of the two aromatic rings (Tyr¹⁸⁹ and Phe⁹ of CCK) are sufficiently different in the human *versus* the rat complexes to explain the mutagenesis results. In fact, according to dynamic simulation experiments, the relative position of Tyr¹⁸⁹ and Phe⁹ of CCK, and therefore the location of CCK, within the binding pocket appears to be at least partially governed by the presence of Met²³⁴ (TM V) in the human CCK2R instead of an isoleucine in the rat receptor, and conversely, the presence of Met¹⁹⁴ (TM IV) in the rat CCK2R instead of a valine in human receptor. In the modeled human CCK2R, Met²³⁴ forms a sulfur- π interaction with Phe³⁴², which in turn can influence the aromatic network comprising residues Phe³⁴², Trp³⁴⁶, Phe²²⁷, and Tyr³⁵⁰ (Fig. 3, B and C). In the rat CCK2R, it is Met¹⁹⁴ that can influence this aromatic network but in an opposite way. Interactions between methionine and aromatic residues, such as Phe and Tyr, are recognized to play an important role in the three-dimensional structure and function of many proteins. For instance, in the CCK1R, a Met residue located in the second extracellular loop was demonstrated to play a key role for correct positioning of Tyr(SO₃H) of CCK toward its interacting partner, Arg¹⁹⁷ (22, 23). In this receptor, another methionine in helix III was demonstrated to govern receptor coupling to G protein by influencing the hydrophobic pocket, which positions Phe of CCK relative to an aromatic residue of helix VI (24). The physicochemical basis of interactions between a sulfur atom and aromatic ring has been investigated and was claimed to explain why, in the protein data base, ~50% of the sulfur atoms are contacting aromatic rings (25).

Analysis of data from studies of other groups reinforces our current findings, showing that conserved residues in the CCK2R among different species contribute differently in CCK high affinity and CCK2R activation. First, although residue Trp³⁴⁶ of the human CCK2R belongs to the aromatic network (Fig. 3, A and B), its exchange for an alanine did not affect pharmacological properties of the receptor (26). In contrast, the corresponding mutation in the rat receptor caused a 34% decrease of inositol phosphate accumulation and a 10-fold decrease of both CCK affinity and potency (27). This is consistent with dynamic simulation data predicting that the C-terminal phenylalanine of CCK makes stacking ring-ring interactions with Tyr¹⁸⁹ and Trp³⁵¹ (corresponding to human Trp³⁴⁶) located in the sixth transmembrane domain. This is also in line with the key role of Tyr¹⁸⁹ in the activation of the rat CCK2R that we documented using site-directed mutagenesis (11). Second, the key role of Phe³⁴² (TM VI) in the aromatic network and the fact that in the human CCK2R this residue interacts with Met²³⁴ (TM V) must be compared with findings that the corresponding residue in the rat sequence (Phe³⁴⁷) is crucial for activation of phospholipase-C by the CCK2R (27, 28). Third, the works of Kopin and colleagues (19, 26) points out the importance of Tyr⁶¹ (junction between TM I and N-terminal

region), Met¹⁸⁶ (TM IV), and Thr¹⁹³ for CCK binding to the human CCK2R. Their data are fully compatible with the refined human CCK2R-CCK complex, which shows hydrogen bonds involving Tyr⁶¹ and Tyr of CCK as well as Thr¹⁹³ and the amide of CCK (Fig. 3A). On the other hand, the role of Met¹⁸⁶ is likely indirect and linked to the aromatic network within the binding pocket. Using NMR nuclear Overhauser enhancement transfer, Mierke and co-worker (29) proposed interactions between Trp and Met of CCK with Pro³⁷¹ and Phe³⁷⁴ (TM VII). In our modeled structure, Nle, which mimics Met of CCK, approximates Pro³⁷¹. It is interesting to note that there is a good overlapping between the binding site for the C-terminal of CCK and the suggested binding site of non-peptide ligands, as indicated by the delete/rescue approach in which deleterious mutations within the receptor were rescued by subsequent modification of the ligand (30).

To conclude, delineation of the CCK binding site of the human CCK2R, using site-directed mutagenesis and docking followed by dynamic simulations, allowed us to demonstrate that, although roughly resembling that of the rat CCK2R, this binding site also displays important distinct structural features that are confirmed by susceptibility to point mutations. These new important data, together with our experience with the CCK1R (31), will be used to understand how some of the so-called non-peptide antagonists present partial agonist activities (7). This goal is of timely importance due to the fact that CCK2R is a biological target of therapeutic interest (6).

REFERENCES

1. Silvente-Poirot, S., Dufresne, M., Vaysse, N., and Fourmy, D. (1993) *Eur. J. Biochem.* **215**, 513–529
2. Noble, F., Wank, S. A., Crawley, J. N., Bradwejn, J., Seroogy, K. B., Hamon, M., and Roques, B. P. (1999) *Pharmacol. Rev.* **51**, 745–781
3. de Weerth, A., Pisegna, J. R., Huppi, K., and Wank, S. A. (1993) *Biochem. Biophys. Res. Commun.* **194**, 811–818
4. Wank, S. A., Pisegna, J. R., and de Weerth, A. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 8691–8695
5. Lee, Y. M., Beinborn, M., McBride, E. W., Lu, M., Kolakowski, L. F., Jr., and Kopin, A. S. (1993) *J. Biol. Chem.* **268**, 8164–8169
6. Herranz, R. (2003) *Med. Res. Rev.* **23**, 559–605
7. Kopin, A. S., McBride, E. W., Schaffer, K., and Beinborn, M. (2000) *Trends Pharmacol. Sci.* **21**, 346–353
8. Beinborn, M., Lee, Y. M., McBride, E. W., Quinn, S. M., and Kopin, A. S. (1993) *Nature* **362**, 348–350
9. Kopin, A. S., McBride, E. W., Gordon, M. C., Quinn, S. M., and Beinborn, M. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 11043–11048
10. Silvente-Poirot, S., Escrieut, C., Gales, C., Fehrentz, J. A., Escherich, A., Wank, S. A., Martinez, J., Moroder, L., Maigret, B., Bouisson, M., Vaysse, N., and Fourmy, D. (1999) *J. Biol. Chem.* **274**, 23191–23197
11. Gales, C., Poirot, M., Taillefer, J., Maigret, B., Martinez, J., Moroder, L., Escrieut, C., Pradayrol, L., Fourmy, D., and Silvente-Poirot, S. (2003) *Mol. Pharmacol.* **63**, 973–982
12. Silvente-Poirot, S., Escrieut, C., and Wank, S. A. (1998) *Mol. Pharmacol.* **54**, 364–371
13. Moroder, L., Wilschowitz, L., Gemeiner, M., Gohring, W., Knof, S., Scharf, R., Thamm, P., Gardner, J. D., Solomon, T. E., and Wunsch, E. (1981) *Hoppe-Seyler's Z. Physiol. Chem.* **362**, 929–942
14. Fourmy, D., Lopez, P., Poirot, S., Jimenez, J., Dufresne, M., Moroder, L., Powers, S. P., and Vaysse, N. (1989) *Eur. J. Biochem.* **185**, 397–403
15. Gigoux, V., Escrieut, C., Fehrentz, J. A., Poirot, S., Maigret, B., Moroder, L., Gully, D., Martinez, J., Vaysse, N., and Fourmy, D. (1999) *J. Biol. Chem.* **274**, 20457–20464
16. Fong, T. M., Yu, H., and Strader, C. D. (1992) *J. Biol. Chem.* **267**, 25668–25671
17. Cascieri, M. A., Huang, R. R., Fong, T. M., Cheung, A. H., Sadowski, S., Ber, E., and Strader, C. D. (1992) *Mol. Pharmacol.* **41**, 1096–1099
18. Oksenberg, D., Marsters, S. A., O'Dowd, B. F., Jin, H., Havlik, S., Peroutka, S. J., and Ashkenazi, A. (1992) *Nature* **360**, 161–163
19. Kopin, A. S., McBride, E. W., Quinn, S. M., Kolakowski, L. F., Jr., and Beinborn, M. (1995) *J. Biol. Chem.* **270**, 5019–5023
20. Anders, J., Bluggel, M., Meyer, H. E., Kuhne, R., ter Laak, A. M., Kojro, E., and Fahrenholz, F. (1999) *Biochemistry* **38**, 6043–6055
21. Jagerschmidt, A., Guillaume-Rousselet, N., Vikland, M. L., Goudreau, N., Maigret, B., and Roques, B. P. (1996) *Eur. J. Pharmacol.* **296**, 97–106
22. Gigoux, V., Escrieut, C., Silvente-Poirot, S., Maigret, B., Gouilleux, L., Fehrentz, J. A., Gully, D., Moroder, L., Vaysse, N., and Fourmy, D. (1998) *J. Biol. Chem.* **273**, 14380–14386
23. Gigoux, V., Maigret, B., Escrieut, C., Silvente-Poirot, S., Bouisson, M., Fehrentz, J. A., Moroder, L., Gully, D., Martinez, J., Vaysse, N., and Fourmy, D. (1999) *Protein Sci.* **8**, 2347–2354
24. Escrieut, C., Gigoux, V., Archer, E., Verrier, S., Maigret, B., Behrendt, R., Moroder, L., Bignon, E., Silvente-Poirot, S., Pradayrol, L., and Fourmy, D. (2002) *J. Biol. Chem.* **277**, 7546–7555
25. Viguera, A. R., and Serrano, L. (1995) *Biochemistry* **34**, 8771–8779
26. Blaker, M., Ren, Y., Gordon, M. C., Hsu, J. E., Beinborn, M., and Kopin, A. S. (1998) *Mol. Pharmacol.* **54**, 857–863
27. Jagerschmidt, A., Guillaume, N., Roques, B. P., and Noble, F. (1998) *Mol. Pharmacol.* **53**, 878–885
28. Pommier, B., Marie-Claire, C., Da Nascimento, S., Wang, H. L., Roques, B. P., and Noble, F. (2003) *J. Neurochem.* **85**, 454–461
29. Giragossian, C., and Mierke, D. F. (2002) *Biochemistry* **41**, 4560–4566
30. Kopin, A. S., McBride, E. W., Chen, C., Freidinger, R. M., Chen, D., Zhao, C. M., and Beinborn, M. (2003) *Proc. Natl. Acad. Sci. U. S. A.* **100**, 5525–5530
31. Archer-Lahlou, E., Escrieut, C., Clerc, P., Martinez, J., Moroder, L., Logsdon, C., Kopin, A., Seva, C., Dufresne, M., Pradayrol, L., Maigret, B., and Fourmy, D. (2005) *J. Biol. Chem.* **280**, 10664–10674